Exelixis
EXEL
#1658
Rank
$10.35 B
Marketcap
$36.25
Share price
1.26%
Change (1 day)
72.62%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : $2.27 Billion USD

According to Exelixis's latest financial reports the company has $2.27 Billion USD in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$$2.26 B-9.02%
2022-12-31$$2.48 B12.57%
2021-12-31$$2.21 B17.64%
2020-12-31$$1.87 B11.46%
2019-12-31$$1.68 B30.95%
2018-12-31$$1.28 B351.8%
2017-12-31$$0.28 B219.04%
2016-12-31$$89.31 M-163.43%
2015-12-31$-$0.15 Billion22.62%
2014-12-31$-$0.12 Billion-273.36%
2013-12-31$$66.23 M-77.66%
2012-12-31$$0.29 B227.07%
2011-12-31$$90.63 M-139.69%
2010-12-31$-$0.23 Billion39.46%
2009-12-31$-$0.17 Billion191.01%
2008-12-31$-$56.27 Million-165.79%
2007-12-31$$85.51 M-5.63%
2006-12-31$$90.61 M58.15%
2005-12-31$$57.29 M13.07%
2004-12-31$$50.67 M-68.62%
2003-12-31$$0.16 B-8.21%
2002-12-31$$0.17 B-25.84%
2001-12-31$$0.23 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
$18.00 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
$78.25 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
$44.56 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
$17.20 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.52 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
$70.15 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
$92.55 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.7 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
$28.84 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA